Cognitive impulsivity in Parkinson's disease patients: assessment and pathophysiology.
Identifieur interne : 000B36 ( PubMed/Checkpoint ); précédent : 000B35; suivant : 000B37Cognitive impulsivity in Parkinson's disease patients: assessment and pathophysiology.
Auteurs : Gabriel Robert [France] ; Dominique Drapier ; Marc Verin ; Bruno Millet ; Jean-Philippe Azulay ; Olivier BlinSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Dopamine Agents.
- chemical , metabolism : Dopamine.
- adverse effects : Deep Brain Stimulation.
- complications : Parkinson Disease.
- etiology : Impulsive Behavior.
- physiology : Cognition, Decision Making.
- therapy : Parkinson Disease.
- Humans, Neuropsychological Tests, Reward.
Abstract
Impulsivity may be induced by therapeutic interventions (dopamine replacement therapies and sub-thalamic nucleus (STN) stimulation) in patients with Parkinson's disease (PD). The present review has two goals. First, to describe the most frequently encountered facets of cognitive impulsivity and to stress the links between cognitive impulsivity and aspects such as reward-related decision making, risk-taking, and time-processing in healthy population. The most widely used related cognitive impulsivity paradigms are presented. Second, to review the results of studies on cognitive impulsivity in healthy volunteers and in patients with PD, the latter support the applicability and clinical relevance of this construct in PD population. Data show that PD treatments may favor impulsivity via different mechanisms. Suggestions on the roles of dopamine and STN in the pathophysiology of cognitive impulsivity are proposed.
DOI: 10.1002/mds.22836
PubMed: 19908312
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:19908312Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cognitive impulsivity in Parkinson's disease patients: assessment and pathophysiology.</title><author><name sortKey="Robert, Gabriel" sort="Robert, Gabriel" uniqKey="Robert G" first="Gabriel" last="Robert">Gabriel Robert</name><affiliation wicri:level="3"><nlm:affiliation>UPCET et Pharmacologie Clinique, CNRS, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UPCET et Pharmacologie Clinique, CNRS, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Drapier, Dominique" sort="Drapier, Dominique" uniqKey="Drapier D" first="Dominique" last="Drapier">Dominique Drapier</name></author><author><name sortKey="Verin, Marc" sort="Verin, Marc" uniqKey="Verin M" first="Marc" last="Verin">Marc Verin</name></author><author><name sortKey="Millet, Bruno" sort="Millet, Bruno" uniqKey="Millet B" first="Bruno" last="Millet">Bruno Millet</name></author><author><name sortKey="Azulay, Jean Philippe" sort="Azulay, Jean Philippe" uniqKey="Azulay J" first="Jean-Philippe" last="Azulay">Jean-Philippe Azulay</name></author><author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19908312</idno><idno type="pmid">19908312</idno><idno type="doi">10.1002/mds.22836</idno><idno type="wicri:Area/PubMed/Corpus">000B34</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B34</idno><idno type="wicri:Area/PubMed/Curation">000A94</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A94</idno><idno type="wicri:Area/PubMed/Checkpoint">000A94</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A94</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cognitive impulsivity in Parkinson's disease patients: assessment and pathophysiology.</title><author><name sortKey="Robert, Gabriel" sort="Robert, Gabriel" uniqKey="Robert G" first="Gabriel" last="Robert">Gabriel Robert</name><affiliation wicri:level="3"><nlm:affiliation>UPCET et Pharmacologie Clinique, CNRS, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UPCET et Pharmacologie Clinique, CNRS, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Drapier, Dominique" sort="Drapier, Dominique" uniqKey="Drapier D" first="Dominique" last="Drapier">Dominique Drapier</name></author><author><name sortKey="Verin, Marc" sort="Verin, Marc" uniqKey="Verin M" first="Marc" last="Verin">Marc Verin</name></author><author><name sortKey="Millet, Bruno" sort="Millet, Bruno" uniqKey="Millet B" first="Bruno" last="Millet">Bruno Millet</name></author><author><name sortKey="Azulay, Jean Philippe" sort="Azulay, Jean Philippe" uniqKey="Azulay J" first="Jean-Philippe" last="Azulay">Jean-Philippe Azulay</name></author><author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cognition (physiology)</term><term>Decision Making (physiology)</term><term>Deep Brain Stimulation (adverse effects)</term><term>Dopamine (metabolism)</term><term>Dopamine Agents (adverse effects)</term><term>Humans</term><term>Impulsive Behavior (etiology)</term><term>Neuropsychological Tests</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (therapy)</term><term>Reward</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Deep Brain Stimulation</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Impulsive Behavior</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Cognition</term><term>Decision Making</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Neuropsychological Tests</term><term>Reward</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Impulsivity may be induced by therapeutic interventions (dopamine replacement therapies and sub-thalamic nucleus (STN) stimulation) in patients with Parkinson's disease (PD). The present review has two goals. First, to describe the most frequently encountered facets of cognitive impulsivity and to stress the links between cognitive impulsivity and aspects such as reward-related decision making, risk-taking, and time-processing in healthy population. The most widely used related cognitive impulsivity paradigms are presented. Second, to review the results of studies on cognitive impulsivity in healthy volunteers and in patients with PD, the latter support the applicability and clinical relevance of this construct in PD population. Data show that PD treatments may favor impulsivity via different mechanisms. Suggestions on the roles of dopamine and STN in the pathophysiology of cognitive impulsivity are proposed.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19908312</PMID><DateCreated><Year>2009</Year><Month>12</Month><Day>28</Day></DateCreated><DateCompleted><Year>2010</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2014</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>16</Issue><PubDate><Year>2009</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Cognitive impulsivity in Parkinson's disease patients: assessment and pathophysiology.</ArticleTitle><Pagination><MedlinePgn>2316-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22836</ELocationID><Abstract><AbstractText>Impulsivity may be induced by therapeutic interventions (dopamine replacement therapies and sub-thalamic nucleus (STN) stimulation) in patients with Parkinson's disease (PD). The present review has two goals. First, to describe the most frequently encountered facets of cognitive impulsivity and to stress the links between cognitive impulsivity and aspects such as reward-related decision making, risk-taking, and time-processing in healthy population. The most widely used related cognitive impulsivity paradigms are presented. Second, to review the results of studies on cognitive impulsivity in healthy volunteers and in patients with PD, the latter support the applicability and clinical relevance of this construct in PD population. Data show that PD treatments may favor impulsivity via different mechanisms. Suggestions on the roles of dopamine and STN in the pathophysiology of cognitive impulsivity are proposed.</AbstractText><CopyrightInformation>(c) 2009 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Robert</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>UPCET et Pharmacologie Clinique, CNRS, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drapier</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Verin</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Millet</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Azulay</LastName><ForeName>Jean-Philippe</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Blin</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003657" MajorTopicYN="N">Decision Making</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046690" MajorTopicYN="N">Deep Brain Stimulation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007175" MajorTopicYN="N">Impulsive Behavior</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012201" MajorTopicYN="N">Reward</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>127</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19908312</ArticleId><ArticleId IdType="doi">10.1002/mds.22836</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Provence-Alpes-Côte d'Azur</li></region><settlement><li>Marseille</li></settlement></list><tree><noCountry><name sortKey="Azulay, Jean Philippe" sort="Azulay, Jean Philippe" uniqKey="Azulay J" first="Jean-Philippe" last="Azulay">Jean-Philippe Azulay</name><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name><name sortKey="Drapier, Dominique" sort="Drapier, Dominique" uniqKey="Drapier D" first="Dominique" last="Drapier">Dominique Drapier</name><name sortKey="Millet, Bruno" sort="Millet, Bruno" uniqKey="Millet B" first="Bruno" last="Millet">Bruno Millet</name><name sortKey="Verin, Marc" sort="Verin, Marc" uniqKey="Verin M" first="Marc" last="Verin">Marc Verin</name></noCountry><country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Robert, Gabriel" sort="Robert, Gabriel" uniqKey="Robert G" first="Gabriel" last="Robert">Gabriel Robert</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B36 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000B36 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:19908312
|texte= Cognitive impulsivity in Parkinson's disease patients: assessment and pathophysiology.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:19908312" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |